Lupin Unit Sues Ranbaxy Over Antara ANDA

Law360, New York (August 10, 2010, 2:41 PM EDT) -- A unit of Indian drugmaker Lupin Ltd. is fighting to block Ranbaxy Laboratories Ltd. from launching a generic version of cholesterol drug Antara.

Lupin Atlantis Holdings SA lodged a patent infringement suit Friday in the U.S. District Court for the District of Delaware in response to Ranbaxy’s abbreviated new drug application seeking federal approval to make and market capsules that contain 43 mg and 130 mg of micronized fenofibrate before a patent covering the drug expires in 2020.

The complaint was filed on behalf of Lupin...
To view the full article, register now.